SLC5A2 and hydrops fetalis: In the 2023 AHA/ACC/HFSA guideline for the management of HF, SGLT2 inhibitors (dapagliflozin and empagliflozin) carry a class IA recommendation in patients with HFpEF to reduce the risk of HF hospitalization or CV death (42).